Sector News

GSK poaches Merck KGaA exec to replace departing U.S. pharma president Bailey

August 13, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

GlaxoSmithKline has seen plenty of changes across its executive ranks over the last couple of years as CEO Emma Walmsley took the helm, but they’re still coming.

Monday, the company said Jack Bailey, its U.S. pharma president and a veteran at the drugmaker, would step down at the end of the year. He’ll be succeeded by Maya Martinez-Davis, who currently serves as the president of Merck KGaA’s Latin America pharma business.

In Bailey, GSK will lose an “exceptional leader” who’s spent more than 10 years at Glaxo since joining the company from Eli Lilly, global pharma president Luke Miels said in a statement. But the pharma giant will have time to ease the transition: Martinez-Davis will come on in mid-September before officially taking the baton Jan. 1. Bailey, meanwhile, will stay on as a strategic consultant through 2020.

In Martinez-Davis, GSK is picking up an exec with experience in one of its key focus areas: oncology. After trading away its cancer assets back in early 2015, Walmsley reprioritized the field last year with pipeline moves and a $5.1 billion Tesaro deal agreement. Now, it’ll have an exec on board who in the past has served as both senior vice president of Merck KGaA’s global oncology business and as a regional president of Pfizer’s oncology portfolio in North America.

“As we continue to grow and reshape our business globally, we are pleased to have found a leader in Maya who will bring a valuable U.S. experience and deep therapy area expertise to expanding our specialty care capabilities and market presence,” Miels said.

Bailey is just one in a sea of leaders who have departed the company since previous CEO Andrew Witty first announced his planned exit. Most recently, longtime Chief Financial Officer Simon Dingemans left in May, and next up is chairman Sir Philip Hampton, who will turn the reins over to ex-Novartis and AstraZeneca Chief Financial Officer Jonathan Symonds Aug. 31.

By: Carly Helfand

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 20, 2019

From evergreening to thicketing: exploring the manipulation of pharma patents

Life sciences

LinkedIn Twitter FacebookThe drug patent system was created to reward pharma companies for innovation and ensure returns on investment, but increasingly companies are manipulating the system using techniques like ‘evergreening’ […]

November 20, 2019

Amgen trims 172 more jobs, this time in operations, R&D and sales

Life sciences

LinkedIn Twitter FacebookAmgen’s top line has suffered from knockoff competition in recent quarters, and now the pain is moving to its payroll. After disclosing almost 150 cuts on the East […]

November 19, 2019

Big Data is the ‘next frontier’ for medicine, says Dexcom CEO

Life sciences

LinkedIn Twitter FacebookThe health care industry will continue to be transformed by the role of Big Data, DexCom CEO Kevin Sayer told CNBC’s Jim Cramer on Wednesday. “This whole integration […]

Subscribe to our Weekly Newsletter

We're easy to reach